ABSTRACT
Schizophrenia (SZ) is hypothesised to represent a costly trade-off in the evolution of the neurodevelopmental ontogenetic mechanisms associated with human-specific cognitive capacities. Human Accelerated Regions (HARs) are evolutionary conserved genomic regions that have accumulated human-specific sequence changes. These evolutionary markers function as neurodevelopmental transcription enhancers and have been associated with the brain’s cortical expansion and connectivity, the processing of neural information, and the risk for SZ. We sought to investigate whether HARs’ polygenic load influenced neuroanatomical measures.
Our sample consisted of 128 patients with SZ and 115 healthy controls with high-resolution structural T1 MRI and genome-wide genotyping data. We extracted the cortical thickness (CT) and surface area (SA) for the 34 Desikan-Killiany regions per hemisphere. We calculated four polygenic risk scores (PRS): SZ genetic load (Global PRSSZ), HARs’ specific variability (HARs PRSSZ), HARs’ variability associated with transcriptional regulatory elements uniquely active in the foetal brain (FB-HARs PRSSZ) and in the adult brain (AB-HARs PRSSZ). Through linear regression analyses, we explored whether these four PRSs modulated CT and SA within diagnostic groups and the PRSs and diagnostic interaction on the cortical measures.
Results indicate that FB-HARs PRSSZ influenced patients’ right SA on the lateral orbitofrontal cortex, the superior temporal cortex, the pars triangularis and the paracentral lobule and that a higher SZ risk load in FB-HARs is associated with lower SA values.
These findings evidence the involvement of the HARs-foetal gene regulatory activity in SA architecture and the evolutionary component of this regulation in SZ. These data emphasise the importance of HARs in the transcriptional regulatory machinery from early neurodevelopment and their role as the bridging point between the neurodevelopmental and evolutionary hypotheses in SZ.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study received project funding from: i) Brain & Behavior Research Foundation (NARSAD Young Investigator Award) to MF-V (grant ID 26206); ii) Instituto de Salud Carlos III (ISCIII) through the contracts FI19/0352 to MG-R, CD22/00106 to MAG-L, and CP20/00072 to MF-V (co-funded by European Regional Development Fund (ERDF)/European Social Fund "Investing in your future"); iii) la "Caixa" Foundation through the Junior Leader Fellowship contract LCF/BQ/PR22/11920017 to PF-C; iv) the Swiss National Science Ambizione grant PZ00P2_185814 to EJC-R; iiv) Julia Gil Pineda Research Fellowship to ER-C; iiiv) the Comissionat per a Universitats i Recerca del DIUE of the Generalitat de Catalunya (Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR, 2021SGR01475). CeGen PRB3 is supported by grant PT17/0019, of the PE I+D+i 2013-2016, funded by ISCIII and ERDF.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All subjects signed a written consent after being fully informed about the procedures and implications of the study, approved by the Germanes Hospitalaries Research Ethics Committee, and performed following its guidelines and in accord with the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
